Literature DB >> 11709492

Requirement of functional ryanodine receptor type 3 for astrocyte migration.

Marina Matyash1, Vitali Matyash, Christiane Nolte, Vincenzo Sorrentino, Helmut Kettenmann.   

Abstract

Astrocyte motility plays an important role in the response of the brain to injury and during regeneration. We used two in vitro assays, a wound-healing model and a chemotaxis assay, to study mechanisms that control astrocyte motility. Ryanodine receptors (RyR), intracellular calcium-release channels, modulate intracellular Ca2+ levels, and also motility: 1) blocking RyR with antagonizing concentration of ryanodine (200 microM) strongly attenuated motility and 2) motility of astrocytes cultured from homozygous RyR type 3 knockout mice was impaired strongly compared with wild-type. In contrast, MIP-1a-induced chemotaxis was neither impaired in the presence of ryanodine nor in the cells from the knockout animals. Reverse transcription-polymerase chain reaction (RT-PCR) analysis combined with Western blotting and immunocytochemistry confirmed the expression of RyR type 3, but not type 1 or 2 in cultured and acutely isolated astrocytes. RyR in astrocytes are linked to Ca2+ signaling because the RyR agonist 4-chloro-m-cresol induced a release of Ca2+ from intracellular stores. These results indicate that astrocytes express only RyR type 3 and that this receptor is important for controlling astrocyte motility.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11709492     DOI: 10.1096/fj.01-0380fje

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  32 in total

1.  Ryanodine receptor expression correlates with tumor grade in breast cancer.

Authors:  Mansoor Abdul; Sian Ramlal; Naseema Hoosein
Journal:  Pathol Oncol Res       Date:  2008-04-23       Impact factor: 3.201

2.  Expression and function of calcium-activated potassium channels in human glioma cells.

Authors:  Amy K Weaver; Valerie C Bomben; Harald Sontheimer
Journal:  Glia       Date:  2006-08-15       Impact factor: 7.452

Review 3.  Astrocytes in Migration.

Authors:  Jiang Shan Zhan; Kai Gao; Rui Chao Chai; Xi Hua Jia; Dao Peng Luo; Guo Ge; Yu Wu Jiang; Yin-Wan Wendy Fung; Lina Li; Albert Cheung Hoi Yu
Journal:  Neurochem Res       Date:  2016-11-11       Impact factor: 3.996

4.  Direct monitoring of ER Ca2+ dynamics reveals that Ca2+ entry induces ER-Ca2+ release in astrocytes.

Authors:  Macarena Rodríguez-Prados; Jonathan Rojo-Ruiz; Javier García-Sancho; María Teresa Alonso
Journal:  Pflugers Arch       Date:  2020-04-03       Impact factor: 3.657

Review 5.  Ryanodine receptor studies using genetically engineered mice.

Authors:  Alexander Kushnir; Matthew J Betzenhauser; Andrew R Marks
Journal:  FEBS Lett       Date:  2010-03-07       Impact factor: 4.124

6.  Matrix metalloproteinase-9 facilitates glial scar formation in the injured spinal cord.

Authors:  Jung-Yu C Hsu; Lilly Y W Bourguignon; Christen M Adams; Karine Peyrollier; Haoqian Zhang; Thomas Fandel; Christine L Cun; Zena Werb; Linda J Noble-Haeusslein
Journal:  J Neurosci       Date:  2008-12-10       Impact factor: 6.167

7.  Distribution of inositol-1,4,5-trisphosphate receptor isotypes and ryanodine receptor isotypes during maturation of the rat hippocampus.

Authors:  D N Hertle; M F Yeckel
Journal:  Neuroscience       Date:  2007-10-03       Impact factor: 3.590

8.  Homeostatic function of astrocytes: Ca(2+) and Na(+) signalling.

Authors:  Vladimir Parpura; Alexei Verkhratsky
Journal:  Transl Neurosci       Date:  2012-12       Impact factor: 1.757

Review 9.  Minding the calcium store: Ryanodine receptor activation as a convergent mechanism of PCB toxicity.

Authors:  Isaac N Pessah; Gennady Cherednichenko; Pamela J Lein
Journal:  Pharmacol Ther       Date:  2009-11-25       Impact factor: 12.310

10.  Glioblastoma cells express functional cell membrane receptors activated by daily used medical drugs.

Authors:  Susanne A Kuhn; Ulrike Mueller; Uwe-K Hanisch; Christian R A Regenbrecht; Ilona Schoenwald; Michael Brodhun; Hartwig Kosmehl; Christian Ewald; Rolf Kalff; Rupert Reichart
Journal:  J Cancer Res Clin Oncol       Date:  2009-06-19       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.